CGEN · Compugen Ltd · Investor Relations

Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI, today announced that management will participate in a fireside chat at the H.C. Wainwright 3 rd Annual AI Based Drug Discovery & Development Conference, being held virtually on October 8-9, 2026. The fireside chat will be held on Thursday, October 8, 2026, at 9:30 AM ET. A live webcast of the presentation will be available on the events page of the Investor Relations section of Compugen's website at www.cgen.com . A replay will be available following the live event . About Compugen Compugen is a clinical-stage therapeutic discovery and development company utilizing Unigen™, its AI-powered computational discovery platform, to identify novel drug targets and to develop therapeutics in the field of cancer immunotherapies. Compugen's innovative immuno-oncology pipeline consists of COM701, rilvegostomig and GS-0321 (previously COM503).

Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI/ML, today announced it will host a virtual key opinion leader (KOL) event on Monday, October 5, 2026 at 8:00 AM ET featuring Oladapo Yeku, M.D., Ph.D., FACP (Harvard Medical School, Massachusetts General Hospital), who will join company management to discuss COM701 and the evolving treatment landscape in ovarian cancer. To register, click here . Dr. Yeku will preview the randomized MAIA-ovarian adaptive platform trial design of COM701, a potential first-in-class anti-PVRIG antibody, evaluating safety and efficacy in the maintenance treatment of relapsed platinum sensitive ovarian cancer (PSOC), with median progression-free survival data from the interim analysis expected by Q1 2027. Compugen's Research and Discovery team will also provide an update on expanded capabilities of Unigen™, its AI/ML-powered target discovery platform, which

Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI, today announced that management will participate in a fireside chat and hold one-on-one meetings at the H.C. Wainwright 28th Annual Global Investment Conference, being held from September 14-16 in New York City. The fireside chat will be held on Monday, September 14, 2026 at 3:30 PM ET. A live webcast of the presentation will be available on the events page of the Investor Relations section of Compugen's website at www.cgen.com . A replay will be available following the live event . Please contact your H.C. Wainwright representative for additional information or to schedule a meeting with Compugen. About Compugen Compugen is a clinical-stage therapeutic discovery and development company utilizing Unigen™, its AI-powered computational discovery platform, to identify novel drug targets and to develop therapeutics in the field of cancer

Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today reported financial results for the second quarter of 2026 and provided a corporate update. "Q2 2026 reflects continued execution across the business," said Eran Ophir, Ph.D., President and CEO of Compugen. "Our MAIA-ovarian trial in platinum-sensitive ovarian cancer remains on track for the interim analysis with median progression-free survival data expected by the first quarter of 2027, which would mark a potential inflection point for COM701 in a patient population with a significant unmet need. Our partnered programs also advanced during the quarter, with AstraZeneca initiating an additional Phase 3 trial with rilvegostomig and presenting new rilvegostomig data at ASCO 2026, and the Gilead-partnered GS-0321 Phase 1 trial progressing as planned. With cash runway expected into 2029, we believe we are well positioned to

Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI/ML, today announced that management will present and hold 1x1 meetings at the BTIG Biotechnology Conference 2026 taking place virtually from July 28-29, 2026. Please reach out to your BTIG representative to request a meeting. A replay for this event will not be available. About Compugen Compugen is a clinical-stage therapeutic discovery and development company utilizing Unigen™, its AI/ML powered computational discovery platform, to identify novel drug targets and to develop therapeutics in the field of cancer immunotherapies. Compugen's innovative immuno-oncology pipeline consists of COM701, rilvegostomig and GS-0321 (previously COM503). COM701, a potential first-in-class anti-PVRIG antibody, is currently being evaluated in a blinded randomized ovarian cancer adaptive platform trial as a single agent in maintenance therapy in relapsed

Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today announced that the Company will release its second quarter 2026 financial results on Monday, August 3, 2026, before the U.S. financial markets open. Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET. To access the live conference call by telephone, please dial 1-866-744-5399 from the U.S., or +972-3-918-0644 internationally. The call will be available via live webcast through Compugen's website, which is located at the following link. Following the live webcast, a replay will be available on the Company's website. About Compugen Compugen is a clinical-stage therapeutic discovery and development company utilizing Unigen™, its AI/ML powered computational discovery platform, to identify novel drug targets and to develop therapeutics in the field of cancer

Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today presented a trial-in-progress poster on the MAIA-ovarian adaptive platform trial of COM701, a potential first-in-class anti-PVRIG antibody, at the ESMO Gynaecological Cancers Congress 2026, in Copenhagen, Denmark. "We believe there is a strong biologic and clinical rationale for the MAIA-ovarian trial in relapsed platinum-sensitive ovarian cancer, where no standard of care for this maintenance setting exists," said Eran Ophir, Ph.D., President and CEO of Compugen. "COM701 is well tolerated and has previously shown consistent, durable responses in heavily pre-treated patients with platinum-resistant ovarian cancer. As highlighted in our poster, the differentiated biology of the PVRIG pathway, together with its high expression in ovarian cancer and prior clinical signals, supports our evaluation of COM701 in the MAIA-ovarian

Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational drug target discovery powered by AI/ML, today announced that it will present a trial-in-progress poster on the MAIA-ovarian Phase 1 study of COM701, a potential first-in-class anti-PVRIG antibody, at the ESMO Gynaecological Cancers Congress 2026, taking place from June 17 to June 19, 2026, in Copenhagen, Denmark. Poster details: Title: MAIA-ovarian (NCT06888921) Adaptive Platform Clinical Trial to Evaluate Safety and Efficacy of COM701 Maintenance Treatment in Relapsed Platinum Sensitive Ovarian Cancer (PSOC) Speaker: Dr. Oladapo Yeku, Massachusetts General Hospital, Boston, MA, U.S. Poster presentation number : 170 Date and time of poster presentation : June 18, 2026, 12:45 - 13:30 CEST Following the presentation, the poster will be available in the publications section of Compugen's website, www.cgen.com About Compugen Compugen is a clinical-stage

Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI/ML, today announced that management will participate in Jones Trading's Mapping the Path from Target to Patient: Fireside Chat Series with Leaders in AI/ ML-based Drug Development on Monday, June 15, 2026, from 10:30-11:00 AM ET. A live webcast will be accessible on the Investor Relations section of the Compugen website at www.cgen.com . A replay will also be available following the live event. About Compugen Compugen is a clinical-stage therapeutic discovery and development company utilizing Unigen ™ , its AI/ML powered computational discovery platform, to identify novel drug targets and to develop therapeutics in the field of cancer immunotherapies. Compugen's innovative immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig and GS-0321 (previously COM503). COM701, a potential first-in-class

COM701 MAIA-ovarian trial actively enrolling patients across all clinical sites in the U.S., Israel, and France; interim analysis on track by Q1 2027 Partner AstraZeneca is advancing rilvegostomig across 11 ongoing Phase 3 trials and presented clinical and pre-clinical rilvegostomig data at AACR 2026, including late-breaking Phase 2 data in HER2-positive gastric cancer (DESTINY-Gastric03), with new data to be released at ASCO 2026 Gilead-partnered GS-0321 Phase 1 trial continues to progress as planned Solid financial position with cash runway expected to fund operations into 2029 Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI/ML, today reported financial results for the first quarter of 2026 and provided a corporate update. "Q1 2026 reflects continued execution across all of our programs in line with our strategic priorities," said Eran Ophir, Ph.D., President and CEO of Compugen.

Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI/ML, today announced that management will present at the 2026 Stifel Virtual Targeted Oncology Forum. The presentation will take place on Tuesday, May 19, 2026, at 10:00-10:25 AM ET. A live webcast will be accessible on the Investor Relations section of the Compugen website at www.cgen.com . A replay will also be available following the live event. About Compugen Compugen is a clinical-stage therapeutic discovery and development company utilizing Unigen ™ , its AI/ML powered computational discovery platform, to identify novel drug targets and to develop therapeutics in the field of cancer immunotherapies. Compugen's innovative immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig and GS-0321 (previously COM503). COM701, a potential first-in-class anti-PVRIG antibody, and COM902, an anti-TIGIT

Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today announced that the Company will release its first quarter 2026 financial results on Monday, May 18, 2026, before the U.S. financial markets open. Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET. To access the live conference call by telephone, please dial 1-866-744-5399 from the U.S., or +972-3-918-0644 internationally. The call will be available via live webcast through Compugen's website, which is located at the following link. Following the live webcast, a replay will be available on the Company's website. About Compugen Compugen is a clinical-stage therapeutic discovery and development company utilizing Unigen™, its AI/ML powered computational discovery platform, to identify novel drug targets and to develop therapeutics in the field of cancer

Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will present at the 25 th Annual Needham Virtual Healthcare Conference. The presentation will take place on Monday, April 13, 2026, at 8:45-9:25 AM ET. A live webcast will be accessible on the Investor Relations section of the Compugen website at www.cgen.com . A replay will also be available following the live event. About Compugen Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable AI/ML powered computational discovery platform (Unigen™) to identify novel drug targets and biological pathways for developing cancer immunotherapies. Compugen has two differentiated Fc-reduced programs targeting TIGIT: COM902, a fully owned Fc-reduced high affinity anti-TIGIT antibody in Phase 1 development and rilvegostomig, an Fc-reduced PD-1/TIGIT bispecific antibody in Phase 3

Strengthened financial position through a non-dilutive transaction with AstraZeneca, monetizing a small portion of rilvegostomig royalties and extending expected cash runway into 2029 Enhanced leadership team with Dr. Eran Ophir appointed President and CEO and Dr. Anat Cohen-Dayag transitioned to Executive Chair Advanced clinical execution, including initiation of trials for wholly owned COM701 (MAIA-ovarian) and Gilead partnered GS-0321 and expansion of the Company's global clinical trial footprint Presented clinical updates for COM701 and GS-0321 at ESMO and SITC 2025, respectively On track to have MAIA-ovarian interim analysis in Q1 2027 Partner AstraZeneca reported promising Phase 2 rilvegostomig data at ESMO 2025, with 10 ongoing Phase 3 clinical trials, and anticipates further Phase 1/2 clinical trial data with rilvegostomig in 2026 Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by

Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today announced that management will participate in the following upcoming investor conferences: Oppenheimer 36th Annual Healthcare Life Sciences Conference Date: Thursday, February 26, 2026 Location: Virtual Format: Fireside chat and 1x1 meetings Fireside chat time: 2 PM ET Leerink Partners 2026 Global Healthcare Conference Date: Monday, March 9, 2026 Location: Miami, Florida, U.S. Format: Fireside chat and 1x1 meetings Fireside chat time: 8:40 AM ET Live webcasts of the fireside chats will be available on the events page of the Investor Relations section of Compugen's website at www.cgen.com . Replays will be available following the live events. About Compugen Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable AI/ML powered

Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today announced that the Company will release its fourth quarter and full year 2025 financial results on Monday, March 2, 2026, before the U.S. financial markets open. Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET. To access the live conference call by telephone, please dial 1-866-744-5399 from the U.S., or +972-3-918-0644 internationally. The call will be available via live webcast through Compugen's website, which is located at the following link. Following the live webcast, a replay will be available on the Company's website. About Compugen Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable AI/ML powered computational discovery platform (Unigen ™ ) to identify novel drug targets and biological

Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today announced the appointment of Michele Holcomb, Ph.D., as a new independent director, effective February 11, 2026. "On behalf of Compugen's Board of Directors, I am delighted to welcome Michele to the Board," said Anat Cohen-Dayag, Ph.D., Executive Chair, Compugen. "Michele brings more than three decades of experience spanning the biotech, pharmaceuticals and healthcare services industries. Her unique blend of strategic insights, corporate development, innovation and firsthand operational experience across multiple executive roles makes her an exceptional addition to Compugen. Coupled with her service on both public and private boards, Michele's broad industry perspective, and ability to guide organizations through value-creating inflection points will meaningfully strengthen the board." "As Compugen enters 2026 from a